S. De Stefani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
S. De Stefani has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Alchiede Simonato
Urology Clinic, Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, 90127 Palermo, Italy
1 shared publication Alice C. J. Hart
Imperial College Healthcare NHS Trust London UK
1 shared publication- Andrea Benelli
Department of Urology, E.O. Ospedali Galliera, Genoa, Italy
1 shared publication - Andrea Gregori
Department of Urology, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy
1 shared publication - Andrea Lissiani
Department of Urologic Surgery, “Luigi Sacco” University Medical Center, Milan, Italy
1 shared publication - Arend Jan Gerard Jansen
Erasmus MC University Medical Center Rotterdam the Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 November 2023
- Published by Wiley in British Journal of Haematology
- Vol. 204 (1) , 324-328
Safety and efficacy of SARS‐CoV‐2 vaccination in patients with immune thrombocytopenia: A two‐centre review
Summary: Multiple studies have reported immune thrombocytopenia (ITP) relapse following SARS‐CoV‐2 vaccination, however baseline ITP relapse rate and antibody response to vaccination are not known. Patients with ITP who received at least one of the first three SARS‐CoV‐2 vaccination doses were included in the study. One hundred and twenty‐four patients met the inclusion criteria. Relapse rate was 4.2% following a first vaccine dose, 9.1% after a second and 2.9% after a third; baseline relapse rate was 7.6%. Ninety‐four per cent of patients who received three vaccine doses developed a clinical antibody response. SARS‐CoV‐2 vaccination appears to be safe and effective in patients with ITP.
- 27 November 2023
- Published by Wiley in British Journal of Haematology
- Vol. 204 (1) , 324-328
Open AccessSafety and efficacy of SARS‐CoV‐2 vaccination in patients with immune thrombocytopenia: A two‐centre review
Summary: Multiple studies have reported immune thrombocytopenia (ITP) relapse following SARS‐CoV‐2 vaccination, however baseline ITP relapse rate and antibody response to vaccination are not known. Patients with ITP who received at least one of the first three SARS‐CoV‐2 vaccination doses were included in the study. One hundred and twenty‐four patients met the inclusion criteria. Relapse rate was 4.2% following a first vaccine dose, 9.1% after a second and 2.9% after a third; baseline relapse rate was 7.6%. Ninety‐four per cent of patients who received three vaccine doses developed a clinical antibody response. SARS‐CoV‐2 vaccination appears to be safe and effective in patients with ITP.
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e817
817 Elective segmental ureterectomy for transitional cell carcinoma of the ureter: Long term follow-up in a 73 patients series
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e817
817 Elective segmental ureterectomy for transitional cell carcinoma of the ureter: Long term follow-up in a 73 patients series